<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03260790</url>
  </required_header>
  <id_info>
    <org_study_id>16-007731</org_study_id>
    <nct_id>NCT03260790</nct_id>
  </id_info>
  <brief_title>Pneumococcal Vaccines in Patients With Asthma</brief_title>
  <official_title>Immunogenicity of PPSV-23 After PCV-13 Vaccination in Adult Asthmatic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators are assessing if patients with asthma respond better to the Pneumovax vaccine
      if they are given Prevnar initially.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized into either PCV13 and PPSV23 (Experimental) or PPSV23 alone
      (Active comparator). At the Week 0 time point, the patients will receive either PCV13
      (Experimental) or PPSV23 (Active comparator) and undergo a blood draw of 5ml for assessment
      of pre-vacation serotype titers. The Active Comparator group will undergo a 5ml draw of blood
      for assessment of titers at week 8, 16, and 24 following vaccination. The Experimental group
      will undergo vaccination with PPSV23 at week 8 with 5 ml blood draw for pneumococcal serotype
      titers as well as a blood draw at week 16 and week 24.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Immune response at week 8</measure>
    <time_frame>Baseline, week 8</time_frame>
    <description>5 ml blood draw for assessment of pneumococcal specific titers, IgG, IgM and IgA. These are all measured as mg/dL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune response</measure>
    <time_frame>week 8</time_frame>
    <description>5 ml blood draw for assessment of IgG specific Antibody titers to all 23 serotypes. These are all measured as mcg/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune response</measure>
    <time_frame>week 16</time_frame>
    <description>5 ml blood draw for assessment of IgG specific Antibody titers to all 23 serotypes. These are all measured as mcg/mL.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>PCV13 and PPSV23</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive PPSV23 primed with PCV13</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PPSV23</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to receive PPSV23 alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PCV13</intervention_name>
    <description>Single 0.5 ml dose of PCV13 administered via intramuscular injection</description>
    <arm_group_label>PCV13 and PPSV23</arm_group_label>
    <other_name>Prevnar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PPSV23</intervention_name>
    <description>Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously</description>
    <arm_group_label>PCV13 and PPSV23</arm_group_label>
    <arm_group_label>PPSV23</arm_group_label>
    <other_name>Pneumovax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Diagnosis of asthma

        Exclusion Criteria:

          -  Research exemption requested

          -  History of PCV-13 vaccination

          -  History of cochlear implant

          -  Cerebrospinal Fluid (CSF) leak

          -  Congestive Heart Failure (CHF)

          -  Diabetes Mellitus (DM)

          -  Chronic Kidney Disease (CKD)

          -  Human Immunodeficiency Virus (HIV)

          -  Common Variable Immune Deficiency (CVID)

          -  Patients who have received the PPSV23 vaccine in the last 5 years

          -  Women who are pregnant will also be excluded from the study by performing 2 point of
             care urine pregnancy tests ( prior to vaccinations)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Avni Y Joshi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kay A Bachman</last_name>
    <phone>507-284-5689</phone>
    <email>bachman.kay@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2017</study_first_submitted>
  <study_first_submitted_qc>August 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2017</study_first_posted>
  <last_update_submitted>January 5, 2018</last_update_submitted>
  <last_update_submitted_qc>January 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Avni Joshi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>Pneumococcal</keyword>
  <keyword>Pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

